New York, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Open Society Foundations today welcome Bard College's successful completion of a landmark endowment challenge first issued in 2021 by Open Society Founder George Soros. By meeting the challenge, Bard has established the first endowment in its history, positioning the college to sustain and expand its mission as an independent institution of higher education centered on the liberal arts and sciences and dedicated to the public interest for generations to come.
The challenge invited Bard to match a $500 million commitment from Open Society by raising an additional $500 million from other donors, securing a $1 billion endowment to support the college's undergraduate and graduate programs, faculty, student scholarships, the arts, and international engagement. Bard's success marks a significant moment for an institution long recognized for its commitment to educational access, academic rigor, and public service. It also reflects Open Society's historical support for higher education and the role of critical thinking in public life.
At a time when American democracy is under strain and colleges and universities face growing political and financial pressure, Bard's endowment underscores the importance of investing in independent higher education as a cornerstone of democratic life.
“Higher education is essential to the future of American democracy,” said Alex Soros, chair of the Open Society Foundations. “Bard will continue to be a place where critical thinking flourishes and students learn why the liberal arts are more important to freedom and the rule of law than ever in today's embattled moment.”
Located in Annandale-on-Hudson, New York, Bard College has played a leading role in advancing liberal arts and sciences education and expanding access to higher education. Its programs include the Bard Prison Initiative, which provides college education to incarcerated students; Bard Early Colleges, which enable public high school students to earn college degrees tuition free in supportive environments; and a wide range of international partnerships focused on expanding educational opportunity for underserved communities.
“Bard is profoundly grateful to George Soros, Alex Soros, and the Open Society Foundations,” said Leon Botstein, president of Bard College. “The response of our donor community, which has given and pledged over $500 million to meet the OSF challenge, affirms George Soros's belief in Bard and its mission. This outpouring of support endorses Bard's excellence and innovation and bodes well for the future of the College.”
About Open Society: The Open Society Foundations, founded by George Soros, are the world's largest private funder of independent groups working for rights, equity, and justice. Every year, the Open Society Foundations give grants to a diverse array of groups and individuals who promote our values—through a unique network that is guided by local voices and global expertise.
About Bard College
Founded in 1860, Bard College is a four-year residential college of the liberal arts and sciences located 90 miles north of New York City. With the addition of the Montgomery Place and Massena properties, Bard's campus consists of more than 1,200 parklike acres in the Hudson River Valley. It offers bachelor of arts, bachelor of science, and bachelor of music degrees, with majors in nearly 40 academic programs; advanced degrees through 13 graduate programs; nine early colleges; and numerous dual-degree programs nationally and internationally.
Contact:
Communications
Open Society Foundations
media@opensocietyfoundations.org
Jennifer Strodl, Director of Communications
Bard College
+1 845-758-7015
jstrodl@bard.edu
-
成功平替国际巨头、韧性增长,嘉为蓝鲸筑牢IT研运行业的长期合作安全屏障成功平替国际巨头、韧性增长,嘉为蓝鲸筑牢IT研运行业的长期合作安全屏障2026-01-22
-
2026 功能食品健康峰会圆满落幕2026 年 1 月 21 日,为期两天的 2026 功能食品健康峰会(FFWS 2026)在泰国曼谷圆满落幕。作为亚太乃至全球功能食品领域的年度旗舰盛会与行业标杆性枢纽平台,本次峰会2026-01-22
-
世索科颁发30万欧元欧内斯特•索尔维奖予庄小威教授 表彰其开创性方法,揭示细胞在何处以及如何发挥功能并响应变化布鲁塞尔2026年1月22日 美通社 -- 世索科通过世索科基金会,将2026年欧内斯特•索尔维奖授予哈佛大学及霍华德•休斯医学研究所的庄小威教授,以表彰其在开发强大的成2026-01-22
-
迈威生物靶向 CDH17 ADC 创新药 7MW4911 完成美国临床试验首例患者给药上海2026年1月22日 美通社 -- 迈威生物(688062.SH),一家全产业链布局的创新型生物制药公司,宣布其靶向 CDH17 ADC 创新药(研发代号:7MW4911)用于晚期结直肠癌及其他晚期2026-01-22
-
重磅喜讯丨 山王果隐龙刺梨酵活原液斩获“健观奖·2025年度健康产品”重磅喜讯丨 山王果隐龙刺梨酵活原液斩获“健观奖·2025年度健康产品”2026-01-22
